Valerie Morisset, PhD is Co-Founder and Chief Scientific Officer of Eliem Therapeutics. Valerie has more than 20 years’ experience in the pharmaceutical industry, with positions of increasing responsibility at Novartis, GSK, Convergence, and Biogen. Prior to joining Eliem, Valerie was a founding venture partner at Bridge Valley Ventures. She co-founded Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team, and was instrumental in the sale of Convergence to Biogen for $675M in 2015. Valerie subsequently joined Biogen in a senior leadership role. She has worked extensively in the field of drug development for Pain and across a number of other therapeutic areas including Neurology, Psychiatry, Gastrointestinal Disorders and Sensory Biology. Valerie trained as an electrophysiologist and completed her PhD at the University of Bordeaux.

Jo Palmer-Phillips, PhD is Chief Development Officer at Eliem Therapeutics.  Joanne is a neuropsychologist with over 18 years’ experience working in clinical development in the pharmaceutical industry with a focus on pain and migraine.  She has held positions in both clinical operations and clinical strategy including leading multidisciplinary clinical teams at Roche, GSK, Convergence Pharmaceuticals and Biogen.  She was a founding member of Convergence Pharmaceuticals Ltd and a member of the leadership team.  As the Head of Clinical Operations at Convergence she was responsible for designing and managing the full-service outsourcing of phase 1 and 2 clinical studies in pain.  She was also responsible for establishing and maintaining the Quality System. 

Amy Chappell, M.D., has 32 years of CNS clinical drug development experience first at Eli Lilly and company (25.5 years), followed by extensive consulting for small and large pharmaceutical companies. Her most recent position was VP, Neuroscience, at PPD, a contract research organization. Amy has deep expertise in translational neuroscience and in all phases of clinical drug development across a wide range of neurological indications including epilepsy, ALS, Parkinson’s, Alzheimer’s, multiple pain types, migraine, and multiple sclerosis. She has interacted with multiple Regulatory Agencies and was the medical lead on the development and NDA submission of duloxetine for fibromyalgia which resulted in an FDA approval. She is the author of many peer-reviewed scientific publications.

Amy is certified by the American Board of Neurology and Psychiatry (neurology with special competency in child), the American Academy of Pediatrics (specialty certification), and by the American Board of Lifestyle Medicine. She has 40 years of clinical practice experience in child and adult neurology and holds active Florida and Indiana medical licenses.

She is a graduate of Antioch College (BS) and the Indiana University School of Medicine (MD). She completed her post-doctoral training at the Johns Hopkins Hospital (pediatric residency and epilepsy fellowship) and the Indiana University Medical Center (neurology residency).

Helen Gaby is the Head of Operations at Eliem Therapeutics.  Helen has over 20 years of experience working in the pharma industry including for SmithKine Beecham and GSK. She was a founder member of Convergence Pharmaceuticals, playing a key role in establishing policies and procedures and then managed the transfer of financial and operational matters to Biogen after the sale of Convergence to Biogen in 2015.  She has a degree in Economics.

David Witty, DPhil is Head of Chemistry – Research, Development and Manufacturing at Eliem Therapeutics. David is also a co-founder of Convergence and Witnet R&D Consultancy and has spent more than 25 years in Pharmaceutical R&D. He has led projects for GSK, Convergence, Biogen and Witnet in areas ranging from anti-infectives, metabolic diseases, cognition, cancer therapeutics and pain. David is the Senior Editor of Progress in Medicinal Chemistry and has published more than 100 primary papers, reviews, books and patents. He gained his first degrees and doctorate in Chemistry from Oxford University and is the recipient of the Royal Society of Chemistry BMCS Lectureship and a Board Member of SCI.

David Mister, MS is Head of Clinical Operations at Eliem Therapeutics. David comes to Eliem with over 20 years of experience in Clinical Development related activities. He started his career as an in-house CRA at Cocensys, a small biopharmaceutical company developing compounds for various neurological disorders. After leaving Cocensys he worked for seven years in various monitoring and project management functions at two CROs, first CroMedica as one of their first US employees, and then PRA International as part of an acquisition. David has spent the last 15 years in several Clinical Development and Operations functions at Allergan in Irvine, California. He has a wide level of management experience working on all levels of the clinical development process from Phase I through III of the development process, through phase IV post-marketing activities. He is located in Orange Country, California.